You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFluticasone Propionate
Accession NumberDB00588  (APRD00065)
TypeSmall Molecule
GroupsApproved
DescriptionFluticasone propionate, a medium-potency synthetic corticosteroid, is used topically to relieve inflammatory and pruritic symptoms of dermatoses and psoriasis, intranasally to manage symptoms of allergic and non-allergic rhinitis, and orally for the treatment of asthma. Fluticasone proprionate is marketed under several different brand names such as Flonase®. Fluticasone propionate is also available as a combination product of azelastine hydrochloride and fluticasone propionate called Dymista™. Dymista™ is indicated in patients over 12 years old for symptomatic relief of seasonal allergic rhinitis.
Structure
Thumb
Synonyms
Cutivate
Fluticason
Fluticasona
Fluticasone
Fluticasone propionate
Fluticasonum
External Identifiers
  • CCI 18781
  • GW 685698X
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cutivatelotion.5 mg/mLtopicalPharma Derm, A Division Of Fougera Pharmaceuticals Inc.2009-10-05Not applicableUs
Cutivatecream0.05 %topicalGlaxosmithkline Inc2004-11-082013-08-01Canada
Cutivatelotion.5 mg/mLtopicalPharma Derm, A Division Of Nycomed Us Inc.2009-10-05Not applicableUs
Cutivatecream.5 mg/gtopicalPharma Derm A Division Of Fougera Pharmaceuticals Inc.1990-12-18Not applicableUs
Cutivateointment.05 mg/gtopicalPharma Derm, A Division Of Fougera Pharmaceuticals Inc.2009-12-14Not applicableUs
Flonasespray, metered50 ug/1nasalGlaxo Smith Kline Llc1994-11-082016-02-28Us
Flonasespray, metered50 ug/1nasalREMEDYREPACK INC.2013-06-11Not applicableUs
Flonase - Aem-sus Nas 50mcg/mdmetered-dose pump50 mcgnasalGlaxosmithkline Inc1993-03-12Not applicableCanada
Flonase Aem-sus 50mcg/aemmetered-dose aerosol; suspension50 mcgnasalGlaxo Canada Inc1993-12-311998-07-30Canada
Flonase Allergy Aqueous Nasal Spraymetered-dose pump50 mcgnasalGlaxosmithkline IncNot applicableNot applicableCanada
Flovent Diskuspowder, metered100 ug/1respiratory (inhalation)Glaxo Smith Kline Llc2008-10-13Not applicableUs
Flovent Diskuspowder100 mcginhalationGlaxosmithkline Inc1998-04-02Not applicableCanada
Flovent Diskuspowder50 mcginhalationGlaxosmithkline Inc1998-04-022015-10-09Canada
Flovent Diskuspowder250 mcginhalationGlaxosmithkline Inc1998-04-02Not applicableCanada
Flovent Diskuspowder, metered50 ug/1respiratory (inhalation)Glaxo Smith Kline Llc2007-05-08Not applicableUs
Flovent Diskuspowder500 mcginhalationGlaxosmithkline Inc1998-04-02Not applicableCanada
Flovent Diskuspowder, metered250 ug/1respiratory (inhalation)Glaxo Smith Kline Llc2008-10-13Not applicableUs
Flovent HFAmetered-dose aerosol50 mcginhalation; oralGlaxosmithkline Inc2001-12-20Not applicableCanada
Flovent HFAaerosol, metered220 ug/1respiratory (inhalation)Glaxo Smith Kline Llc2007-01-25Not applicableUs
Flovent HFAaerosol, metered110 ug/1respiratory (inhalation)Physicians Total Care, Inc.2005-07-13Not applicableUs
Flovent HFAmetered-dose aerosol125 mcginhalation; oralGlaxosmithkline Inc2001-12-20Not applicableCanada
Flovent HFAaerosol, metered220 ug/1respiratory (inhalation)Physicians Total Care, Inc.2006-07-05Not applicableUs
Flovent HFAaerosol, metered44 ug/1respiratory (inhalation)Glaxo Smith Kline Llc2007-04-06Not applicableUs
Flovent HFAmetered-dose aerosol250 mcginhalation; oralGlaxosmithkline Inc2001-12-20Not applicableCanada
Flovent HFAaerosol, metered44 ug/1respiratory (inhalation)Physicians Total Care, Inc.2009-02-26Not applicableUs
Flovent HFAaerosol, metered110 ug/1respiratory (inhalation)Glaxo Smith Kline Llc2007-01-29Not applicableUs
Flovent HFAaerosol, metered110 ug/1respiratory (inhalation)Lake Erie Medical & Surgical Supply DBA Quality Care Products LLC2007-01-29Not applicableUs
Flovent Inhalers - Aem Inh-orl 125mcg/aemmetered-dose aerosol125 mcginhalation; oralGlaxosmithkline Inc1998-08-182003-06-10Canada
Flovent Inhalers - Aem Inh-orl 250mcg/aemmetered-dose aerosol250 mcginhalation; oralGlaxosmithkline Inc1998-09-212003-03-27Canada
Flovent Inhalers - Aem Inh-orl 25mcg/aemmetered-dose aerosol25 mcginhalation; oralGlaxosmithkline Inc1998-11-272003-06-10Canada
Flovent Inhalers - Aem Inh-orl 50mcg/aemmetered-dose aerosol50 mcginhalation; oralGlaxosmithkline Inc1998-04-092003-06-10Canada
Flovent Inhalers-aem Inh-orl 25mcg/actuationmetered-dose aerosol25 mcginhalation; oralGlaxo Canada Inc1995-12-311999-08-12Canada
Flovent Inhalers-aem Inh-orl 50mcg/actuationmetered-dose aerosol50 mcginhalation; oralGlaxo Canada Inc1995-12-311998-07-30Canada
Flovent Inhalers-aem Inh-orl125mcg/actuationmetered-dose aerosol125 mcginhalation; oralGlaxo Canada Inc1995-12-311999-08-12Canada
Flovent Inhalers-aem Inh-orl250mcg/actuationmetered-dose aerosol250 mcginhalation; oralGlaxo Canada Inc1995-12-311999-08-12Canada
Floventhfa HFAaerosol, metered44 ug/1respiratory (inhalation)REMEDYREPACK INC.2013-06-11Not applicableUs
Fluticasone Propionatelotion.5 mg/mLtopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.2009-10-05Not applicableUs
Nu-fluticasonespray, metered dose50 mcgnasalNu Pharm IncNot applicableNot applicableCanada
Ratio-fluticasonemetered-dose pump50 mcgnasalTeva Canada Limited2007-06-07Not applicableCanada
Teva-fluticasonemetered-dose pump50 mcgnasalTeva Canada LimitedNot applicableNot applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-fluticasonespray, metered dose50 mcgnasalApotex Inc2007-07-05Not applicableCanada
Fluticasonespray, metered50 ug/1nasalMorton Grove Pharmaceuticals, Inc.2012-01-09Not applicableUs
Fluticasonespray, metered50 ug/1nasalDIRECT RX2014-01-01Not applicableUs
Fluticasonespray, metered50 ug/1nasalMedsource Pharmaceuticals2012-01-09Not applicableUs
Fluticasone Propionatespray, metered50 ug/.1gnasalRebel Distributors Corp2008-01-16Not applicableUs
Fluticasone Propionatespray, metered50 ug/1nasalRoxane Laboratories, Inc2006-02-22Not applicableUs
Fluticasone Propionatespray, metered50 ug/.1gnasalPreferred Pharmaceuticals, Inc2012-01-18Not applicableUs
Fluticasone Propionatespray, metered50 ug/.1gnasalREMEDYREPACK INC.2013-06-11Not applicableUs
Fluticasone Propionatecream.5 mg/gtopicalDIRECT RX2014-01-01Not applicableUs
Fluticasone Propionatespray, metered50 ug/.1gnasalLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-12Not applicableUs
Fluticasone Propionatespray, metered50 ug/1nasalPhysicians Total Care, Inc.2006-03-08Not applicableUs
Fluticasone Propionatecream.5 mg/gtopicalG&W Laboratories, Inc.2006-06-30Not applicableUs
Fluticasone Propionatecream.5 mg/gtopicalPerrigo New York Inc2006-09-13Not applicableUs
Fluticasone Propionateointment.05 mg/gtopicalPerrigo New York Inc2007-07-09Not applicableUs
Fluticasone Propionatespray, metered50 ug/1nasalApotex Corp.2007-09-19Not applicableUs
Fluticasone Propionatecream.5 mg/gtopicalGlobal Pharmaceuticals, Division of Impax Laboratories Inc.2004-05-14Not applicableUs
Fluticasone Propionatespray, metered50 ug/1nasalREMEDYREPACK INC.2013-06-11Not applicableUs
Fluticasone Propionatespray, metered50 ug/.1gnasalProficient Rx LP2008-01-16Not applicableUs
Fluticasone Propionatespray, metered50 ug/.1gnasalHi Tech Pharmacal Co., Inc.2008-01-16Not applicableUs
Fluticasone Propionateointment.05 mg/gtopicalGW Laboratories, Inc2006-05-31Not applicableUs
Fluticasone Propionatespray, metered50 ug/.1gnasalClinical Solutions Wholesale2008-01-16Not applicableUs
Fluticasone Propionatelotion.5 mg/mLtopicalPerrigo New York Inc2013-08-08Not applicableUs
Fluticasone Propionatespray, metered50 ug/1nasalApotex Corp.2007-09-19Not applicableUs
Fluticasone Propionatecream.5 mg/gtopicalPhysicians Total Care, Inc.2006-09-13Not applicableUs
Fluticasone Propionatecream.5 mg/gtopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.2004-05-14Not applicableUs
Fluticasone Propionatespray, metered50 ug/.1gnasalUnit Dose Services2008-01-16Not applicableUs
Fluticasone Propionatelotion.5 mg/mLtopicalGlenmark Pharmaceuticals Inc., Usa2011-10-13Not applicableUs
Fluticasone Propionatespray, metered50 ug/1nasalBlenheim Pharmacal, Inc.2007-09-19Not applicableUs
Fluticasone Propionatespray, metered50 ug/1nasalGolden State Medical Supply, Inc.2011-06-02Not applicableUs
Fluticasone Propionateointment.05 mg/gtopicalPhysicians Total Care, Inc.2005-10-20Not applicableUs
Fluticasone Propionateointment.05 mg/gtopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.2004-05-14Not applicableUs
Fluticasone Propionatespray, metered50 ug/1nasalProficient Rx LP2007-09-19Not applicableUs
Fluticasone Propionateointment.05 mg/gtopicalTaro Pharmaceuticals U.S.A., Inc.2005-06-14Not applicableUs
Fluticasone Propionatespray, metered50 ug/1nasalPreferred Pharmaceuticals, Inc.2013-04-22Not applicableUs
TicanasekitPure Tek Corporation2016-01-11Not applicableUs
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Childrens Flonase Allergy Reliefspray, metered50 ug/1nasalGlaxo Smith Kline Consumer Healthcare Holdings (Us) Llc2016-02-29Not applicableUs
Clarispray Nasal Allergyspray, metered50 ug/1nasalBayer Health Care Llc2016-03-112016-03-17Us
Flonase Allergy Reliefspray, metered50 ug/1nasalGlaxo Smith Kline Consumer Healthcare Holdings (Us) Llc2014-12-04Not applicableUs
Flonaseallergy Relief Allergy Reliefspray, metered50 ug/1nasalREMEDYREPACK INC.2016-02-15Not applicableUs
Fluticasone Propionatespray, metered50 ug/1nasalRugby Laboratories2016-02-29Not applicableUs
Fluticasone Propionatespray, metered50 ug/1nasalChain Drugs Consortium, Llc2016-02-29Not applicableUs
Fluticasone Propionatespray, metered50 ug/1nasalCVS Pharmacy2015-07-21Not applicableUs
Unapproved/Other Products Not Available
International Brands
NameCompany
EzicasIntas
FlixonaseGlaxoSmithKline
FlixotideGlaxoSmithKline
FloventGlaxoSmithKline
FLOVENTHFANot Available
FlunaseGlaxoSmithKline
NasofanTeva
PirinaseGlaxoSmithKline
SeretideGlaxoSmithKline
Brand mixtures
NameLabellerIngredients
Advair 100 DiskusGlaxosmithkline Inc
Advair 125Glaxosmithkline Inc
Advair 250Glaxosmithkline Inc
Advair 250 DiskusGlaxosmithkline Inc
Advair 500 DiskusGlaxosmithkline Inc
Advair DiskusGlaxo Smith Kline Llc
Advair HFAGlaxo Smith Kline Llc
Advairdiskus DiskusREMEDYREPACK INC.
DymistaMeda Pharmaceuticals Inc.
SaltsNot Available
Categories
UNIIO2GMZ0LF5W
CAS number80474-14-2
WeightAverage: 500.571
Monoisotopic: 500.184429407
Chemical FormulaC25H31F3O5S
InChI KeyInChIKey=WMWTYOKRWGGJOA-CENSZEJFSA-N
InChI
InChI=1S/C25H31F3O5S/c1-5-20(31)33-25(21(32)34-12-26)13(2)8-15-16-10-18(27)17-9-14(29)6-7-22(17,3)24(16,28)19(30)11-23(15,25)4/h6-7,9,13,15-16,18-19,30H,5,8,10-12H2,1-4H3/t13-,15+,16+,18+,19+,22+,23+,24+,25+/m1/s1
IUPAC Name
(1R,2S,8S,10S,11S,13R,14R,15S,17S)-1,8-difluoro-14-{[(fluoromethyl)sulfanyl]carbonyl}-17-hydroxy-2,13,15-trimethyl-5-oxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-14-yl propanoate
SMILES
[H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[[email protected]](O)[C@@]1(F)[C@@]2([H])C[[email protected]](F)C2=CC(=O)C=C[C@]12C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as steroid esters. These are compounds containing a steroid moiety which bears a carboxylic acid ester group.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassSteroid esters
Direct ParentSteroid esters
Alternative Parents
Substituents
  • Steroid ester
  • Androgen-skeleton
  • Androstane-skeleton
  • 11-hydroxysteroid
  • 11-beta-hydroxysteroid
  • Oxosteroid
  • Hydroxysteroid
  • Halo-steroid
  • 6-halo-steroid
  • 9-halo-steroid
  • 3-oxosteroid
  • 3-oxo-delta-1,4-steroid
  • Delta-1,4-steroid
  • Cyclic alcohol
  • Cyclic ketone
  • Thiocarboxylic acid ester
  • Secondary alcohol
  • Ketone
  • Halohydrin
  • Fluorohydrin
  • Carboxylic acid ester
  • Sulfenyl compound
  • Thioether
  • Thiocarboxylic acid or derivatives
  • Monocarboxylic acid or derivatives
  • Carboxylic acid derivative
  • Halomethane
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Alkyl halide
  • Alkyl fluoride
  • Alcohol
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptors
Pharmacology
IndicationFluticasone propionate, a medium-potency synthetic corticosteroid, is used topically to relieve inflammatory and pruritic symptoms of dermatoses and psoriasis, intranasally to manage symptoms of allergic and non-allergic rhinitis, and orally for the maintenance treatment of asthma as prophylactic therapy and for patients requiring oral corticosteroid therapy for asthma.
PharmacodynamicsFluticasone is an extremely potent vasoconstrictor and anti-inflammatory agent. Its effectiveness in inhaled forms is due to its direct local effect.
Mechanism of actionBinds to the glucocorticoid receptor. Unbound corticosteroids cross the membranes of cells such as mast cells and eosinophils, binding with high affinity to glucocorticoid receptors (GR). The results include alteration of transcription and protein synthesis, a decreased release of leukocytic acid hydrolases, reduction in fibroblast proliferation, prevention of macrophage accumulation at inflamed sites, reduction of collagen deposition, interference with leukocyte adhesion to the capillary wall, reduction of capillary membrane permeability and subsequent edema, reduction of complement components, inhibition of histamine and kinin release, and interference with the formation of scar tissue. In the management of asthma, the glucocorticoid receptor complexes down-regulates proinflammatory mediators such as interleukin-(IL)-1, 3, and 5, and up-regulates anti-inflammatory mediators such as IkappaB [inhibitory molecule for nuclear factor kappaB1], IL-10, and IL-12. The antiinflammatory actions of corticosteroids are also thought to involve inhibition of cytosolic phospholipase A2 (through activation of lipocortin-1 (annexin)) which controls the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.
Related Articles
AbsorptionThe extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle and the integrity of the epidermal barrier. Bioavailability, intranasal = <2%; Oral bioavailability is negligible and the major circulating entity is an inactive metabolite.
Volume of distribution

IV administration = 4.2 L/kg

Protein binding91%
Metabolism

Fluticasone propionate is metabolized in the liver by cytochrome P450 3A4-mediated hydrolysis of the 5-fluoromethyl carbothioate grouping. This transformation occurs in 1 metabolic step to produce the inactive 17-(beta)-carboxylic acid metabolite, the only known metabolite detected in man.

SubstrateEnzymesProduct
Fluticasone Propionate
fluticasone 17beta-carboxylic acidDetails
Route of eliminationLess than 5% of the oral dose was excreted in the urine as metabolites. The rest of the dose is excreted in the feces and parent drug and metabolites.
Half lifeTerminal elimination half-life = 7.8 hours
Clearance

The total blood clearance of fluticasone propionate is high (average, 1,093 mL/min), with renal clearance accounting for less than 0.02% of the total.

ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9964
Blood Brain Barrier+0.9701
Caco-2 permeable+0.5417
P-glycoprotein substrateSubstrate0.7099
P-glycoprotein inhibitor IInhibitor0.7192
P-glycoprotein inhibitor IINon-inhibitor0.8636
Renal organic cation transporterNon-inhibitor0.8689
CYP450 2C9 substrateNon-substrate0.868
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.7407
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorInhibitor0.8988
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8682
Ames testNon AMES toxic0.798
CarcinogenicityNon-carcinogens0.8901
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.3753 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.99
hERG inhibition (predictor II)Non-inhibitor0.6125
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Glaxosmithkline
  • Glaxo group ltd dba glaxosmithkline
  • Altana inc
  • G and w laboratories inc
  • Kv pharmaceutical co
  • Perrigo new york inc
  • Tolmar inc
  • Nycomed us inc
  • Taro pharmaceutical industries ltd
  • Apotex inc richmond hill
  • Hi tech pharmacal co inc
  • Roxane laboratories inc
Packagers
Dosage forms
FormRouteStrength
Powderinhalation
Aerosol, metered doseinhalation
Powderoral; respiratory (inhalation)
Powderrespiratory (inhalation)
Aerosol, meteredrespiratory (inhalation)
Spray, metered dosenasal50 mcg
Creamtopical0.05 %
Spray, meterednasal
Spray, metered dosenasal
Metered-dose pumpnasal50 mcg
Metered-dose aerosol; suspensionnasal50 mcg
Powderinhalation100 mcg
Powderinhalation250 mcg
Powderinhalation50 mcg
Powderinhalation500 mcg
Powder, meteredrespiratory (inhalation)100 ug/1
Powder, meteredrespiratory (inhalation)250 ug/1
Powder, meteredrespiratory (inhalation)50 ug/1
Aerosol, meteredrespiratory (inhalation)110 ug/1
Aerosol, meteredrespiratory (inhalation)220 ug/1
Aerosol, meteredrespiratory (inhalation)44 ug/1
Metered-dose aerosolinhalation; oral125 mcg
Metered-dose aerosolinhalation; oral250 mcg
Metered-dose aerosolinhalation; oral50 mcg
Metered-dose aerosolinhalation; oral25 mcg
Creamtopical.5 mg/g
Lotiontopical.5 mg/mL
Ointmenttopical.05 mg/g
Spray, meterednasal50 ug/.1g
Spray, meterednasal50 ug/1
Kit
Prices
Unit descriptionCostUnit
Fluticasone propionate powder1500.0USD g
Cutivate 0.05% Lotion 120ml Bottle454.6USD bottle
Advair Diskus 60 500-50 mcg/dose Aerosol Disp Pack328.14USD disp
Advair Diskus 60 250-50 mcg/dose Aerosol Disp Pack249.48USD disp
Flovent HFA 220 mcg/act Aerosol 12 gm Inhaler237.67USD inhaler
Cutivate 0.05% Cream 60 gm Tube217.11USD tube
Advair Diskus 60 100-50 mcg/dose Aerosol Disp Pack200.79USD disp
Advair Diskus 14 500-50 mcg/dose Aerosol Disp Pack156.64USD disp
Flovent HFA 110 mcg/act Aerosol 12 gm Inhaler153.01USD inhaler
Cutivate 0.005% Ointment 60 gm Tube128.28USD tube
Flovent HFA 44 mcg/act Aerosol 10.6 gm Inhaler114.27USD inhaler
Flovent Diskus 60 50 mcg/blist Aerosol Inhaler104.74USD inhaler
Flonase 50 mcg/act Suspension 16 gm Bottle94.59USD bottle
Fluticasone Propionate 50 mcg/act Suspension 16 gm Bottle78.28USD bottle
Cutivate 0.05% Cream 30 gm Tube62.99USD tube
Fluticasone Propionate 0.005% Ointment 60 gm Tube56.27USD tube
Fluticasone Propionate 0.05% Cream 60 gm Tube56.27USD tube
Cutivate 0.005% Ointment 30 gm Tube44.99USD tube
Fluticasone Propionate 0.005% Ointment 30 gm Tube35.67USD tube
Fluticasone Propionate 0.05% Cream 30 gm Tube35.67USD tube
Cutivate 0.005% Ointment 15 gm Tube32.99USD tube
Cutivate 0.05% Cream 15 gm Tube32.99USD tube
Advair hfa 230-21 mcg inhaler25.04USD g
Fluticasone Propionate 0.005% Ointment 15 gm Tube23.14USD tube
Fluticasone Propionate 0.05% Cream 15 gm Tube23.14USD tube
Advair hfa 115-21 mcg inhaler18.13USD g
Flovent hfa 220 mcg inhaler15.54USD g
Advair hfa 45-21 mcg inhaler14.59USD g
Flovent hfa 110 mcg inhaler12.26USD g
Flovent hfa 44 mcg inhaler10.99USD g
Flonase 0.05% nasal spray5.68USD g
Advair 500-50 diskus5.26USD each
Advair 250-50 diskus4.0USD each
Cutivate 0.05% cream3.48USD g
Advair 100-50 diskus3.22USD each
Flovent 250 mcg diskus2.45USD each
Flovent 100 mcg diskus1.83USD each
Flovent 50 mcg diskus1.74USD each
Flovent Diskus 500 mcg/dose Metered Inhalation Powder1.55USD dose
Flovent Diskus 250 mcg/dose Metered Inhalation Powder0.77USD dose
Flovent Hfa 250 mcg/dose Metered Dose Aerosol0.77USD dose
Flovent Hfa 125 mcg/dose Metered Dose Aerosol0.39USD dose
Flovent Hfa 50 mcg/dose Metered Dose Aerosol0.22USD dose
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2125667 No2000-03-132012-12-04Canada
CA2317999 No2004-11-092020-09-11Canada
US5873360 Yes1996-08-232016-08-23Us
US6161724 Yes1998-07-162018-07-16Us
US6170717 Yes1998-06-232018-06-23Us
US6315173 Yes1998-06-232018-06-23Us
US6431168 Yes1998-12-082018-12-08Us
US6435372 Yes1998-07-162018-07-16Us
US6510969 Yes1998-06-232018-06-23Us
US6743413 Yes2001-12-012021-12-01Us
US6938796 Yes1998-07-162018-07-16Us
US6966467 Yes1998-06-232018-06-23Us
US6997349 Yes1998-07-162018-07-16Us
US7107986 Yes1998-12-082018-12-08Us
US7143908 Yes1998-07-162018-07-16Us
US7300669 No1999-10-202019-10-20Us
US7350676 Yes1999-02-242019-02-24Us
US7500444 Yes2006-08-262026-08-26Us
US7832351 Yes2003-12-192023-12-19Us
US8163723 No2003-08-292023-08-29Us
US8168620 No2006-02-242026-02-24Us
US9259428 No2003-06-132023-06-13Us
USRE40045 No1993-09-072010-09-07Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point272-273 °CNot Available
water solubility0.51 mg/L (insoluble)Not Available
logP3.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0114 mg/mLALOGPS
logP3.69ALOGPS
logP3.72ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)13.56ChemAxon
pKa (Strongest Basic)-3.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area80.67 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity121.65 m3·mol-1ChemAxon
Polarizability49.26 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Joseph Kaspi, Oded Arad, Michael Brand, Moty Shookrun, Simona Malka, Mohammed Alnabari, Shalom Hazan, Vlado Malesevic, “Synthesis and powder preparation of fluticasone propionate.” U.S. Patent US20060009435, issued January 12, 2006.

US20060009435
General ReferencesNot Available
External Links
ATC CodesR03AK11R01AD08R03AK06R01AD58R03BA05D07AC17
AHFS Codes
  • 52:08.08
  • 68:04.00
  • 84:06.00
PDB EntriesNot Available
FDA labelDownload (159 KB)
MSDSDownload (39 KB)
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with 1,10-Phenanthroline.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Fluticasone Propionate.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Fluticasone Propionate.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Fluticasone Propionate.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Fluticasone Propionate.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Fluticasone Propionate.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Fluticasone Propionate.
AldesleukinFluticasone Propionate may decrease the antineoplastic activities of Aldesleukin.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Fluticasone Propionate.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Fluticasone Propionate.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Fluticasone Propionate.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Fluticasone Propionate.
Aluminum hydroxideThe bioavailability of Fluticasone Propionate can be decreased when combined with Aluminum hydroxide.
Aluminum phosphateThe bioavailability of Fluticasone Propionate can be decreased when combined with Aluminum phosphate.
AmbenoniumThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Ambenonium.
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Fluticasone Propionate.
AmiodaroneThe serum concentration of Fluticasone Propionate can be increased when it is combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Fluticasone Propionate.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Fluticasone Propionate.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Fluticasone Propionate.
AmoxapineThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Fluticasone Propionate.
Amphotericin BFluticasone Propionate may increase the hypokalemic activities of Amphotericin B.
AprepitantThe serum concentration of Fluticasone Propionate can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Fluticasone Propionate.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Fluticasone Propionate.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Fluticasone Propionate.
AtazanavirThe serum concentration of Fluticasone Propionate can be increased when it is combined with Atazanavir.
AtomoxetineThe metabolism of Fluticasone Propionate can be decreased when combined with Atomoxetine.
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Fluticasone Propionate.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Fluticasone Propionate.
AzelastineFluticasone Propionate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Fluticasone Propionate.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Fluticasone Propionate.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Fluticasone Propionate.
BazedoxifeneThe serum concentration of Fluticasone Propionate can be increased when it is combined with Bazedoxifene.
BendroflumethiazideFluticasone Propionate may increase the hypokalemic activities of Bendroflumethiazide.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Fluticasone Propionate.
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Fluticasone Propionate.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Fluticasone Propionate.
BexaroteneThe serum concentration of Fluticasone Propionate can be decreased when it is combined with Bexarotene.
Bismuth SubcitrateThe bioavailability of Fluticasone Propionate can be decreased when combined with Bismuth Subcitrate.
BoceprevirThe serum concentration of Fluticasone Propionate can be increased when it is combined with Boceprevir.
BortezomibThe metabolism of Fluticasone Propionate can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Fluticasone Propionate can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fluticasone Propionate.
BrimonidineThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Fluticasone Propionate.
BrompheniramineThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Fluticasone Propionate.
BumetanideFluticasone Propionate may increase the hypokalemic activities of Bumetanide.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Fluticasone Propionate.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Fluticasone Propionate.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Fluticasone Propionate.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Fluticasone Propionate.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Fluticasone Propionate.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Fluticasone Propionate.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Fluticasone Propionate.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Fluticasone Propionate.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Fluticasone Propionate.
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Fluticasone Propionate.
Calcium carbonateThe bioavailability of Fluticasone Propionate can be decreased when combined with Calcium carbonate.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Fluticasone Propionate.
CarbinoxamineThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Fluticasone Propionate.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Fluticasone Propionate.
CeritinibFluticasone Propionate may increase the hyperglycemic activities of Ceritinib.
CeritinibThe serum concentration of Fluticasone Propionate can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Fluticasone Propionate.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Fluticasone Propionate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Fluticasone Propionate.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Fluticasone Propionate.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Fluticasone Propionate.
ChlorothiazideFluticasone Propionate may increase the hypokalemic activities of Chlorothiazide.
ChlorotrianiseneThe serum concentration of Fluticasone Propionate can be increased when it is combined with Chlorotrianisene.
ChlorphenamineThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Chlorphenamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Fluticasone Propionate.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Fluticasone Propionate.
ChlorthalidoneFluticasone Propionate may increase the hypokalemic activities of Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Fluticasone Propionate.
CholestyramineCholestyramine can cause a decrease in the absorption of Fluticasone Propionate resulting in a reduced serum concentration and potentially a decrease in efficacy.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Fluticasone Propionate.
CitalopramThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Citalopram.
ClarithromycinThe serum concentration of Fluticasone Propionate can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Fluticasone Propionate can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Fluticasone Propionate.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Fluticasone Propionate.
ClomipramineThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Fluticasone Propionate.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Fluticasone Propionate.
ClotrimazoleThe metabolism of Fluticasone Propionate can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Fluticasone Propionate.
CobicistatThe serum concentration of Fluticasone Propionate can be increased when it is combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Fluticasone Propionate.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Fluticasone Propionate.
ColesevelamColesevelam can cause a decrease in the absorption of Fluticasone Propionate resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Fluticasone Propionate resulting in a reduced serum concentration and potentially a decrease in efficacy.
ConivaptanThe serum concentration of Fluticasone Propionate can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Fluticasone Propionate can be increased when it is combined with Conjugated Equine Estrogens.
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Fluticasone Propionate.
CoumaphosThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Coumaphos.
CrizotinibThe metabolism of Fluticasone Propionate can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fluticasone Propionate.
CyclosporineThe metabolism of Fluticasone Propionate can be decreased when combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Fluticasone Propionate.
DabrafenibThe serum concentration of Fluticasone Propionate can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fluticasone Propionate.
DapoxetineThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Dapoxetine.
DarunavirThe serum concentration of Fluticasone Propionate can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Fluticasone Propionate can be increased when it is combined with Dasatinib.
DecamethoniumThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Decamethonium.
DeferasiroxThe serum concentration of Fluticasone Propionate can be decreased when it is combined with Deferasirox.
DeferasiroxThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Deferasirox.
DelavirdineThe metabolism of Fluticasone Propionate can be decreased when combined with Delavirdine.
DemecariumThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Demecarium.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Fluticasone Propionate.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Fluticasone Propionate.
DesipramineThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Fluticasone Propionate.
DexamethasoneThe serum concentration of Fluticasone Propionate can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fluticasone Propionate.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Fluticasone Propionate.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Fluticasone Propionate.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Fluticasone Propionate.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Fluticasone Propionate.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Fluticasone Propionate.
DichlorvosThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Dichlorvos.
DienestrolThe serum concentration of Fluticasone Propionate can be increased when it is combined with Dienestrol.
DiethylstilbestrolThe serum concentration of Fluticasone Propionate can be increased when it is combined with Diethylstilbestrol.
DifenoxinThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Difenoxin.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Fluticasone Propionate.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Fluticasone Propionate.
DihydroergotamineThe metabolism of Fluticasone Propionate can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Fluticasone Propionate.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Fluticasone Propionate.
DihydrotestosteroneFluticasone Propionate may increase the fluid retaining activities of Dihydrotestosterone.
DiltiazemThe metabolism of Fluticasone Propionate can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Fluticasone Propionate.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Fluticasone Propionate.
DonepezilThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Donepezil.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Fluticasone Propionate.
DoxepinThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Doxepin.
DoxycyclineThe metabolism of Fluticasone Propionate can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Fluticasone Propionate.
DoxylamineThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Fluticasone Propionate.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Fluticasone Propionate.
DronedaroneThe metabolism of Fluticasone Propionate can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Fluticasone Propionate.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Fluticasone Propionate.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Fluticasone Propionate.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Fluticasone Propionate.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Fluticasone Propionate.
EchothiophateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Echothiophate.
EdrophoniumThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Edrophonium.
EfavirenzThe serum concentration of Fluticasone Propionate can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Efavirenz.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Fluticasone Propionate.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Fluticasone Propionate.
EnzalutamideThe serum concentration of Fluticasone Propionate can be decreased when it is combined with Enzalutamide.
ErythromycinThe metabolism of Fluticasone Propionate can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Fluticasone Propionate can be decreased when it is combined with Eslicarbazepine acetate.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Fluticasone Propionate.
EstradiolThe serum concentration of Fluticasone Propionate can be increased when it is combined with Estradiol.
EstriolThe serum concentration of Fluticasone Propionate can be increased when it is combined with Estriol.
EstroneThe serum concentration of Fluticasone Propionate can be increased when it is combined with Estrone.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Fluticasone Propionate.
Etacrynic acidFluticasone Propionate may increase the hypokalemic activities of Etacrynic acid.
EthanolFluticasone Propionate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Fluticasone Propionate.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fluticasone Propionate.
Ethinyl EstradiolThe serum concentration of Fluticasone Propionate can be increased when it is combined with Ethinyl Estradiol.
EthosuximideThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Fluticasone Propionate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Fluticasone Propionate.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Fluticasone Propionate.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Fluticasone Propionate.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Fluticasone Propionate.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Fluticasone Propionate.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Fluticasone Propionate.
EtoperidoneThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Fluticasone Propionate.
EtravirineThe serum concentration of Fluticasone Propionate can be decreased when it is combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Fluticasone Propionate.
FenfluramineThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Fluticasone Propionate.
FenthionThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Fenthion.
FexofenadineThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Flibanserin.
FluconazoleThe metabolism of Fluticasone Propionate can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Fluticasone Propionate.
FlunarizineThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Fluticasone Propionate.
FluoxetineThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Fluoxetine.
FluoxymesteroneFluticasone Propionate may increase the fluid retaining activities of Fluoxymesterone.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Fluticasone Propionate.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Fluticasone Propionate.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Fluticasone Propionate.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Fluvoxamine.
FluvoxamineThe metabolism of Fluticasone Propionate can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Fluticasone Propionate can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Fluticasone Propionate can be increased when it is combined with Fosaprepitant.
FosphenytoinThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Fluticasone Propionate.
FurosemideFluticasone Propionate may increase the hypokalemic activities of Furosemide.
Fusidic AcidThe serum concentration of Fluticasone Propionate can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Fluticasone Propionate.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with gabapentin enacarbil.
GalantamineThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Galantamine.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Gallamine Triethiodide.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Fluticasone Propionate.
GenisteinThe serum concentration of Fluticasone Propionate can be increased when it is combined with Genistein.
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Ginkgo biloba.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Fluticasone Propionate.
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Fluticasone Propionate.
GuanfacineThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Fluticasone Propionate.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Fluticasone Propionate.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Fluticasone Propionate.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Fluticasone Propionate.
HexestrolThe serum concentration of Fluticasone Propionate can be increased when it is combined with Hexestrol.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Fluticasone Propionate.
Huperzine AThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Huperzine A.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Fluticasone Propionate.
HydrochlorothiazideFluticasone Propionate may increase the hypokalemic activities of Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Fluticasone Propionate.
HydroflumethiazideFluticasone Propionate may increase the hypokalemic activities of Hydroflumethiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Fluticasone Propionate.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Fluticasone Propionate.
HydroxyzineThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Hydroxyzine.
IdelalisibThe serum concentration of Fluticasone Propionate can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Iloperidone.
ImatinibThe metabolism of Fluticasone Propionate can be decreased when combined with Imatinib.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Fluticasone Propionate.
IndacaterolIndacaterol may increase the hypokalemic activities of Fluticasone Propionate.
IndalpineThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Indalpine.
IndapamideFluticasone Propionate may increase the hypokalemic activities of Indapamide.
IndinavirThe serum concentration of Fluticasone Propionate can be increased when it is combined with Indinavir.
IsavuconazoniumThe metabolism of Fluticasone Propionate can be decreased when combined with Isavuconazonium.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Fluticasone Propionate.
IsoflurophateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Isoflurophate.
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Fluticasone Propionate.
IsradipineThe metabolism of Fluticasone Propionate can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Fluticasone Propionate can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Fluticasone Propionate can be increased when it is combined with Ivacaftor.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Fluticasone Propionate.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Fluticasone Propionate.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Fluticasone Propionate.
KetoconazoleThe serum concentration of Fluticasone Propionate can be increased when it is combined with Ketoconazole.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Fluticasone Propionate.
LevetiracetamThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Fluticasone Propionate.
LevocabastineThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Fluticasone Propionate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Fluticasone Propionate.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Fluticasone Propionate.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Fluticasone Propionate.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Fluticasone Propionate.
LopinavirThe serum concentration of Fluticasone Propionate can be increased when it is combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Fluticasone Propionate.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Fluticasone Propionate.
LovastatinThe metabolism of Fluticasone Propionate can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Fluticasone Propionate.
Lu AA21004The risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Lu AA21004.
LuliconazoleThe serum concentration of Fluticasone Propionate can be increased when it is combined with Luliconazole.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Fluticasone Propionate.
MagaldrateThe bioavailability of Fluticasone Propionate can be decreased when combined with Magaldrate.
Magnesium carbonateThe bioavailability of Fluticasone Propionate can be decreased when combined with Magnesium carbonate.
Magnesium hydroxideThe bioavailability of Fluticasone Propionate can be decreased when combined with Magnesium hydroxide.
Magnesium oxideThe bioavailability of Fluticasone Propionate can be decreased when combined with Magnesium oxide.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Fluticasone Propionate.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Magnesium Sulfate.
Magnesium TrisilicateThe bioavailability of Fluticasone Propionate can be decreased when combined with Magnesium Trisilicate.
MalathionThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Malathion.
MaprotilineThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Fluticasone Propionate.
MefloquineThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Mefloquine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Fluticasone Propionate.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Fluticasone Propionate.
MemantineThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Memantine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Fluticasone Propionate.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Fluticasone Propionate.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Fluticasone Propionate.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Fluticasone Propionate.
MestranolThe serum concentration of Fluticasone Propionate can be increased when it is combined with Mestranol.
MetaxaloneThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Fluticasone Propionate.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Fluticasone Propionate.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Fluticasone Propionate.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Fluticasone Propionate.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Fluticasone Propionate.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Fluticasone Propionate.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Fluticasone Propionate.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Fluticasone Propionate.
MethsuximideThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Methsuximide.
MethyclothiazideFluticasone Propionate may increase the hypokalemic activities of Methyclothiazide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Fluticasone Propionate.
MethyltestosteroneFluticasone Propionate may increase the fluid retaining activities of Methyltestosterone.
MetolazoneFluticasone Propionate may increase the hypokalemic activities of Metolazone.
MetyrosineFluticasone Propionate may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Fluticasone Propionate.
MifepristoneThe metabolism of Fluticasone Propionate can be decreased when combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Milnacipran.
MinaprineThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Minaprine.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Fluticasone Propionate.
MirtazapineFluticasone Propionate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Fluticasone Propionate.
MitotaneThe serum concentration of Fluticasone Propionate can be decreased when it is combined with Mitotane.
MivacuriumMivacurium may increase the adverse neuromuscular activities of Fluticasone Propionate.
ModafinilThe serum concentration of Fluticasone Propionate can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Fluticasone Propionate.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Fluticasone Propionate.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Fluticasone Propionate.
NabiloneThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Nabilone.
NafcillinThe serum concentration of Fluticasone Propionate can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Fluticasone Propionate.
NefazodoneThe serum concentration of Fluticasone Propionate can be increased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Fluticasone Propionate can be increased when it is combined with Nelfinavir.
NeostigmineThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Neostigmine.
NetupitantThe serum concentration of Fluticasone Propionate can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Fluticasone Propionate can be decreased when combined with Nevirapine.
NicorandilThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Nicorandil.
NilotinibThe metabolism of Fluticasone Propionate can be decreased when combined with Nilotinib.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Fluticasone Propionate.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Fluticasone Propionate.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Fluticasone Propionate.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Fluticasone Propionate.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Fluticasone Propionate.
OlanzapineThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Olanzapine.
OlaparibThe metabolism of Fluticasone Propionate can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Fluticasone Propionate.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Fluticasone Propionate.
OrphenadrineFluticasone Propionate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Fluticasone Propionate.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Fluticasone Propionate.
OsimertinibThe serum concentration of Fluticasone Propionate can be increased when it is combined with Osimertinib.
OxandroloneFluticasone Propionate may increase the fluid retaining activities of Oxandrolone.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Fluticasone Propionate.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Fluticasone Propionate.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Fluticasone Propionate.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Fluticasone Propionate.
OxymetholoneFluticasone Propionate may increase the fluid retaining activities of Oxymetholone.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Fluticasone Propionate.
PalbociclibThe serum concentration of Fluticasone Propionate can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Fluticasone Propionate.
ParaldehydeFluticasone Propionate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Fluticasone Propionate.
ParoxetineThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Fluticasone Propionate.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Fluticasone Propionate.
PerampanelThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Fluticasone Propionate.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Fluticasone Propionate.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Fluticasone Propionate.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Fluticasone Propionate.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Fluticasone Propionate.
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Fluticasone Propionate.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Fluticasone Propionate.
PhysostigmineThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Physostigmine.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Fluticasone Propionate.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Fluticasone Propionate.
PipotiazineThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Pipotiazine.
PiretanideFluticasone Propionate may increase the hypokalemic activities of Piretanide.
PizotifenThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Pizotifen.
Polyestradiol phosphateThe serum concentration of Fluticasone Propionate can be increased when it is combined with Polyestradiol phosphate.
PolythiazideFluticasone Propionate may increase the hypokalemic activities of Polythiazide.
PomalidomideThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Pomalidomide.
PosaconazoleThe serum concentration of Fluticasone Propionate can be increased when it is combined with Posaconazole.
PramipexoleFluticasone Propionate may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Fluticasone Propionate.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Fluticasone Propionate.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Fluticasone Propionate.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Fluticasone Propionate.
PrimidoneThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Fluticasone Propionate.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fluticasone Propionate.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Fluticasone Propionate.
PromethazineThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Fluticasone Propionate.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Fluticasone Propionate.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Fluticasone Propionate.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Fluticasone Propionate.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Fluticasone Propionate.
PyridostigmineThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Pyridostigmine.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Fluticasone Propionate.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Fluticasone Propionate.
QuinestrolThe serum concentration of Fluticasone Propionate can be increased when it is combined with Quinestrol.
QuinethazoneFluticasone Propionate may increase the hypokalemic activities of Quinethazone.
Rabies vaccineThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Rabies vaccine.
RamelteonThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Ramelteon.
RanolazineThe metabolism of Fluticasone Propionate can be decreased when combined with Ranolazine.
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Fluticasone Propionate.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Fluticasone Propionate.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Fluticasone Propionate.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Fluticasone Propionate.
RifabutinThe serum concentration of Fluticasone Propionate can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Fluticasone Propionate can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Fluticasone Propionate can be decreased when it is combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Fluticasone Propionate.
RitonavirThe serum concentration of Fluticasone Propionate can be increased when it is combined with Ritonavir.
RivastigmineThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Rivastigmine.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Fluticasone Propionate.
RopiniroleFluticasone Propionate may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Fluticasone Propionate.
RotigotineFluticasone Propionate may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Fluticasone Propionate.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Fluticasone Propionate.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Fluticasone Propionate.
SaquinavirThe serum concentration of Fluticasone Propionate can be increased when it is combined with Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fluticasone Propionate.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Fluticasone Propionate.
SertralineThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Fluticasone Propionate.
SildenafilThe metabolism of Fluticasone Propionate can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Fluticasone Propionate can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Fluticasone Propionate can be increased when it is combined with Simeprevir.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Fluticasone Propionate.
Sodium phenylbutyrateThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Fluticasone Propionate.
St. John's WortThe serum concentration of Fluticasone Propionate can be decreased when it is combined with St. John&#39;s Wort.
StanozololFluticasone Propionate may increase the fluid retaining activities of Stanozolol.
StiripentolThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Fluticasone Propionate.
SulfisoxazoleThe metabolism of Fluticasone Propionate can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Fluticasone Propionate.
SuvorexantThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Suvorexant.
Synthetic Conjugated Estrogens, AThe serum concentration of Fluticasone Propionate can be increased when it is combined with Synthetic Conjugated Estrogens, A.
Synthetic Conjugated Estrogens, BThe serum concentration of Fluticasone Propionate can be increased when it is combined with Synthetic Conjugated Estrogens, B.
TacrineThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Tacrine.
TapentadolThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Tasimelteon.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Fluticasone Propionate.
TelaprevirThe serum concentration of Fluticasone Propionate can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Fluticasone Propionate can be increased when it is combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Fluticasone Propionate.
TestosteroneFluticasone Propionate may increase the fluid retaining activities of Testosterone.
TetrabenazineThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Fluticasone Propionate.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Fluticasone Propionate.
ThalidomideFluticasone Propionate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Fluticasone Propionate.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Fluticasone Propionate.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Fluticasone Propionate.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Fluticasone Propionate.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Fluticasone Propionate.
TiagabineThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Tiagabine.
TiboloneThe serum concentration of Fluticasone Propionate can be increased when it is combined with Tibolone.
TiclopidineThe metabolism of Fluticasone Propionate can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Fluticasone Propionate.
TipranavirThe serum concentration of Fluticasone Propionate can be increased when it is combined with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Tizanidine.
TocilizumabThe serum concentration of Fluticasone Propionate can be decreased when it is combined with Tocilizumab.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Fluticasone Propionate.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Fluticasone Propionate.
TorasemideFluticasone Propionate may increase the hypokalemic activities of Torasemide.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Fluticasone Propionate.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Fluticasone Propionate.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fluticasone Propionate.
TrazodoneThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Fluticasone Propionate.
TrichlorfonThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Trichlorfon.
TrichlormethiazideFluticasone Propionate may increase the hypokalemic activities of Trichlormethiazide.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Fluticasone Propionate.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fluticasone Propionate.
TrimipramineThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Fluticasone Propionate.
TubocurarineThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Tubocurarine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Fluticasone Propionate.
VenlafaxineThe metabolism of Fluticasone Propionate can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Fluticasone Propionate can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Vilazodone.
VoriconazoleThe serum concentration of Fluticasone Propionate can be increased when it is combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Vortioxetine.
WarfarinFluticasone Propionate may increase the anticoagulant activities of Warfarin.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Fluticasone Propionate.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Fluticasone Propionate.
ZeranolThe serum concentration of Fluticasone Propionate can be increased when it is combined with Zeranol.
ZiconotideThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Zimelidine.
ZiprasidoneThe metabolism of Fluticasone Propionate can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Fluticasone Propionate.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Fluticasone Propionate.
ZonisamideThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Fluticasone Propionate.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Fluticasone Propionate.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Fluticasone Propionate.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon grow...
Gene Name:
NR3C1
Uniprot ID:
P04150
Molecular Weight:
85658.57 Da
References
  1. Andersson O, Cassel TN, Gronneberg R, Bronnegard M, Stierna P, Nord M: In vivo modulation of glucocorticoid receptor mRNA by inhaled fluticasone propionate in bronchial mucosa and blood lymphocytes in subjects with mild asthma. J Allergy Clin Immunol. 1999 Apr;103(4):595-600. [PubMed:10200007 ]
  2. Lumry WR: A review of the preclinical and clinical data of newer intranasal steroids used in the treatment of allergic rhinitis. J Allergy Clin Immunol. 1999 Oct;104(4 Pt 1):S150-8. [PubMed:10518812 ]
  3. Zhang X, Moilanen E, Kankaanranta H: Beclomethasone, budesonide and fluticasone propionate inhibit human neutrophil apoptosis. Eur J Pharmacol. 2001 Nov 23;431(3):365-71. [PubMed:11730731 ]
  4. Hogger P, Rohdewald P: Binding kinetics of fluticasone propionate to the human glucocorticoid receptor. Steroids. 1994 Oct;59(10):597-602. [PubMed:7878687 ]
  5. Johnson M: Fluticasone propionate: safety profile. Cutis. 1996 Feb;57(2 Suppl):10-2. [PubMed:8646863 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Progesterone receptor isoform B (PRB) is involved activation of c-SRC/MAPK signaling on hormone stimulation.Isoform A: inactive in stimulating c-Src/MAPK signaling on hormone stimulation.Isoform 4: Increases mitochondrial ...
Gene Name:
PGR
Uniprot ID:
P06401
Molecular Weight:
98979.96 Da
References
  1. Issar M, Sahasranaman S, Buchwald P, Hochhaus G: Differences in the glucocorticoid to progesterone receptor selectivity of inhaled glucocorticoids. Eur Respir J. 2006 Mar;27(3):511-6. [PubMed:16507850 ]
  2. Austin RJ, Maschera B, Walker A, Fairbairn L, Meldrum E, Farrow SN, Uings IJ: Mometasone furoate is a less specific glucocorticoid than fluticasone propionate. Eur Respir J. 2002 Dec;20(6):1386-92. [PubMed:12503693 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Phospholipase a2 activity
Specific Function:
Selectively hydrolyzes arachidonyl phospholipids in the sn-2 position releasing arachidonic acid. Together with its lysophospholipid activity, it is implicated in the initiation of the inflammatory response.
Gene Name:
PLA2G4A
Uniprot ID:
P47712
Molecular Weight:
85238.2 Da
References
  1. Sano A, Munoz NM, Sano H, Choi J, Zhu X, Jacobs B, Leff AR: Inhibition of cPLA2 translocation and leukotriene C4 secretion by fluticasone propionate in exogenously activated human eosinophils. Am J Respir Crit Care Med. 1999 Jun;159(6):1903-9. [PubMed:10351938 ]
  2. Myo S, Zhu X, Myou S, Meliton AY, Liu J, Boetticher E, Lambertino AT, Xu C, Munoz NM, Leff AR: Additive blockade of beta 2-integrin adhesion of eosinophils by salmeterol and fluticasone propionate. Eur Respir J. 2004 Apr;23(4):511-7. [PubMed:15083746 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Zinc ion binding
Specific Function:
Receptor for both mineralocorticoids (MC) such as aldosterone and glucocorticoids (GC) such as corticosterone or cortisol. Binds to mineralocorticoid response elements (MRE) and transactivates target genes. The effect of MC is to increase ion and water transport and thus raise extracellular fluid volume and blood pressure and lower potassium levels.
Gene Name:
NR3C2
Uniprot ID:
P08235
Molecular Weight:
107066.575 Da
References
  1. Austin RJ, Maschera B, Walker A, Fairbairn L, Meldrum E, Farrow SN, Uings IJ: Mometasone furoate is a less specific glucocorticoid than fluticasone propionate. Eur Respir J. 2002 Dec;20(6):1386-92. [PubMed:12503693 ]
  2. Issar M, Sahasranaman S, Buchwald P, Hochhaus G: Differences in the glucocorticoid to progesterone receptor selectivity of inhaled glucocorticoids. Eur Respir J. 2006 Mar;27(3):511-6. [PubMed:16507850 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Pearce RE, Leeder JS, Kearns GL: Biotransformation of fluticasone: in vitro characterization. Drug Metab Dispos. 2006 Jun;34(6):1035-40. Epub 2006 Mar 24. [PubMed:16565171 ]
  2. Murai T, Reilly CA, Ward RM, Yost GS: The inhaled glucocorticoid fluticasone propionate efficiently inactivates cytochrome P450 3A5, a predominant lung P450 enzyme. Chem Res Toxicol. 2010 Aug 16;23(8):1356-64. doi: 10.1021/tx100124k. [PubMed:20707410 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Pearce RE, Leeder JS, Kearns GL: Biotransformation of fluticasone: in vitro characterization. Drug Metab Dispos. 2006 Jun;34(6):1035-40. Epub 2006 Mar 24. [PubMed:16565171 ]
  2. Murai T, Reilly CA, Ward RM, Yost GS: The inhaled glucocorticoid fluticasone propionate efficiently inactivates cytochrome P450 3A5, a predominant lung P450 enzyme. Chem Res Toxicol. 2010 Aug 16;23(8):1356-64. doi: 10.1021/tx100124k. [PubMed:20707410 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Pearce RE, Leeder JS, Kearns GL: Biotransformation of fluticasone: in vitro characterization. Drug Metab Dispos. 2006 Jun;34(6):1035-40. Epub 2006 Mar 24. [PubMed:16565171 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Steroid binding
Specific Function:
Major transport protein for glucocorticoids and progestins in the blood of almost all vertebrate species.
Gene Name:
SERPINA6
Uniprot ID:
P08185
Molecular Weight:
45140.49 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 26, 2016 03:28